Efficacy of azithromycin in a murine toxoplasmosis model, employing a Toxoplasma gondii strain from Turkey

Değerli, Kenan; Kilimcioğlu, Ali Ahmet; Kurt, Özgür; Tamay, A.Taylan; Özbilgin, Ahmet

doi:10.1016/s0001-706x(03)00194-3

Cited by 39 publications

(30 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, folinic acid should be supplemented to reduce the risk of bone marrow suppression (Montoya and Liesenfeld, 2004;Ku et al, 2009). Moreover, this regimen is commonly associated with many adverse effects such as haematological toxicity, hypersensitivity (McLeod et al, 2006), intolerance (Montoya and Liesenfeld, 2004), bone marrow suppression and teratogenic effects in the first trimester of pregnancy (Degerli et al, 2003;Schmidt et al, 2006). In certain circumstances, clindamycin, a protein synthesis inhibitor, may also be indicated, but its efficacy is limited, requiring the administration of relatively large amounts of the drug.…”

Section: Introductionmentioning

confidence: 99%

Could miltefosine be used as a therapy for toxoplasmosis?

Eissa

Barakat

Amer

et al. 2015

Experimental Parasitology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Could miltefosine be used as a therapy for toxoplasmosis?

Eissa

Barakat

Amer

et al. 2015

Experimental Parasitology

View full text Add to dashboard Cite

“…Furthermore, administration is required only once per day [11-13]. Azithromycin also inhibits protein synthesis in the plasmodial apicoplast and, thus, has activity against both Plasmodium falciparum and P. vivax [12] .…”

Section: Introductionmentioning

confidence: 99%

Azithromycin is able to control Toxoplasma gondii infection in human villous explants

et al. 2014

View full text Add to dashboard Cite

BackgroundAlthough Toxoplasma gondii infection is normally asymptomatic, severe cases of toxoplasmosis may occur in immunosuppressed patients or congenitally infected newborns. When a fetal infection is established, the recommended treatment is a combination of pyrimethamine, sulfadiazine and folinic acid (PSA). The aim of the present study was to evaluate the efficacy of azithromycin to control T. gondii infection in human villous explants.MethodsCultures of third trimester human villous explants were infected with T. gondii and simultaneously treated with either PSA or azithromycin. Proliferation of T. gondii, as well as production of cytokines and hormones by chorionic villous explants, was analyzed.ResultsTreatment with either azithromycin or PSA was able to control T. gondii infection in villous explants. After azithromycin or PSA treatment, TNF-α, IL-17A or TGF-β1 levels secreted by infected villous explants did not present significant differences. However, PSA-treated villous explants had decreased levels of IL-10 and increased IL-12 levels, while treatment with azithromycin increased production of IL-6. Additionally, T. gondii-infected villous explants increased secretion of estradiol, progesterone and HCG + β, while treatments with azithromycin or PSA reduced secretion of these hormones concurrently with decrease of parasite load.ConclusionsIn conclusion, these results suggest that azithromycin may be defined as an effective alternative drug to control T. gondii infection at the fetal-maternal interface.

show abstract

“…3 Besides this, the current chemotherapy against human toxoplasmosis involve undesirable side effects and it is not effective in eliminating the parasite located in the central nervous system. 5,6 Recent studies using hydroxyurea (HU) demonstrate its efficacy, in vitro, in eliminating the intracellular parasites of T. gondii, Trypanosoma cruzi and Leishmania amazonensis (Fig. 1a).…”

Section: Introductionmentioning

confidence: 99%